nodes	percent_of_prediction	percent_of_DWPC	metapath
Octreotide—SSTR4—digestive system—systemic scleroderma	0.0133	0.204	CbGeAlD
Octreotide—MPO—artery—systemic scleroderma	0.0096	0.147	CbGeAlD
Octreotide—MPO—endothelium—systemic scleroderma	0.00811	0.124	CbGeAlD
Octreotide—MPO—blood vessel—systemic scleroderma	0.00748	0.114	CbGeAlD
Octreotide—SSTR2—digestive system—systemic scleroderma	0.00731	0.112	CbGeAlD
Octreotide—SSTR1—lung—systemic scleroderma	0.00718	0.11	CbGeAlD
Octreotide—MPO—connective tissue—systemic scleroderma	0.00383	0.0586	CbGeAlD
Octreotide—MPO—IL23-mediated signaling events—STAT4—systemic scleroderma	0.00355	0.0514	CbGpPWpGaD
Octreotide—MPO—skin of body—systemic scleroderma	0.00346	0.0529	CbGeAlD
Octreotide—MPO—Folate Metabolism—CSF1—systemic scleroderma	0.00306	0.0444	CbGpPWpGaD
Octreotide—MPO—digestive system—systemic scleroderma	0.00277	0.0423	CbGeAlD
Octreotide—MPO—lung—systemic scleroderma	0.00231	0.0354	CbGeAlD
Octreotide—MPO—C-MYB transcription factor network—COL1A2—systemic scleroderma	0.0023	0.0334	CbGpPWpGaD
Octreotide—SSTR1—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.00219	0.0318	CbGpPWpGaD
Octreotide—SSTR2—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.00179	0.026	CbGpPWpGaD
Octreotide—MPO—IL23-mediated signaling events—CCL2—systemic scleroderma	0.00164	0.0238	CbGpPWpGaD
Octreotide—SSTR4—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.00163	0.0236	CbGpPWpGaD
Octreotide—SSTR1—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.00138	0.02	CbGpPWpGaD
Octreotide—MPO—Vitamin B12 Metabolism—CCL2—systemic scleroderma	0.00127	0.0184	CbGpPWpGaD
Octreotide—MPO—IL23-mediated signaling events—IL1B—systemic scleroderma	0.00125	0.0181	CbGpPWpGaD
Octreotide—SSTR3—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.00124	0.0179	CbGpPWpGaD
Octreotide—SSTR1—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.00118	0.0172	CbGpPWpGaD
Octreotide—SSTR2—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.00113	0.0164	CbGpPWpGaD
Octreotide—SSTR4—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.00111	0.0162	CbGpPWpGaD
Octreotide—SSTR4—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.00109	0.0158	CbGpPWpGaD
Octreotide—SSTR5—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.00105	0.0152	CbGpPWpGaD
Octreotide—MPO—Folate Metabolism—CCL2—systemic scleroderma	0.00103	0.015	CbGpPWpGaD
Octreotide—SSTR2—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.000969	0.0141	CbGpPWpGaD
Octreotide—MPO—Vitamin B12 Metabolism—IL1B—systemic scleroderma	0.000963	0.014	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—RHOB—systemic scleroderma	0.000921	0.0134	CbGpPWpGaD
Octreotide—SSTR3—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.000844	0.0122	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—RHOB—systemic scleroderma	0.000837	0.0121	CbGpPWpGaD
Octreotide—SSTR4—GPCR ligand binding—EDN1—systemic scleroderma	0.000832	0.0121	CbGpPWpGaD
Octreotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000828	0.012	CbGpPWpGaD
Octreotide—MPO—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000821	0.0119	CbGpPWpGaD
Octreotide—SSTR1—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.000809	0.0117	CbGpPWpGaD
Octreotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000794	0.0115	CbGpPWpGaD
Octreotide—MPO—Folate Metabolism—IL1B—systemic scleroderma	0.000784	0.0114	CbGpPWpGaD
Octreotide—SSTR4—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000747	0.0108	CbGpPWpGaD
Octreotide—SSTR1—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	0.000719	0.0104	CbGpPWpGaD
Octreotide—SSTR5—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.000718	0.0104	CbGpPWpGaD
Octreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000704	0.0102	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—RHOB—systemic scleroderma	0.000698	0.0101	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—RHOB—systemic scleroderma	0.000669	0.00971	CbGpPWpGaD
Octreotide—SSTR2—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.000663	0.00961	CbGpPWpGaD
Octreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.00065	0.00942	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—SMAD7—systemic scleroderma	0.000639	0.00926	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—RHOB—systemic scleroderma	0.000634	0.00919	CbGpPWpGaD
Octreotide—SSTR3—GPCR ligand binding—EDN1—systemic scleroderma	0.000631	0.00915	CbGpPWpGaD
Octreotide—MPO—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000623	0.00903	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—RHOB—systemic scleroderma	0.000608	0.00881	CbGpPWpGaD
Octreotide—SSTR1—GPCR ligand binding—EDN1—systemic scleroderma	0.000605	0.00877	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—RHOB—systemic scleroderma	0.000594	0.00861	CbGpPWpGaD
Octreotide—SSTR2—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	0.000588	0.00853	CbGpPWpGaD
Octreotide—SSTR4—GPCR ligand binding—CCL2—systemic scleroderma	0.000569	0.00825	CbGpPWpGaD
Octreotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000566	0.00821	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—RHOB—systemic scleroderma	0.000548	0.00794	CbGpPWpGaD
Octreotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000543	0.00787	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—RHOB—systemic scleroderma	0.000539	0.00782	CbGpPWpGaD
Octreotide—SSTR5—GPCR ligand binding—EDN1—systemic scleroderma	0.000536	0.00778	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—RHOB—systemic scleroderma	0.000498	0.00721	CbGpPWpGaD
Octreotide—SSTR2—GPCR ligand binding—EDN1—systemic scleroderma	0.000495	0.00718	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—RHOB—systemic scleroderma	0.000494	0.00717	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—SMAD7—systemic scleroderma	0.000484	0.00702	CbGpPWpGaD
Octreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000482	0.00698	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—EDN1—systemic scleroderma	0.00047	0.00682	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—HSPG2—systemic scleroderma	0.000466	0.00676	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—SMAD7—systemic scleroderma	0.000464	0.00673	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CSK—systemic scleroderma	0.00045	0.00653	CbGpPWpGaD
Octreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000444	0.00644	CbGpPWpGaD
Octreotide—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000436	0.000503	CcSEcCtD
Octreotide—Irritability—Methotrexate—systemic scleroderma	0.000435	0.000503	CcSEcCtD
Octreotide—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000435	0.000502	CcSEcCtD
Octreotide—Feeling abnormal—Leflunomide—systemic scleroderma	0.000433	0.0005	CcSEcCtD
Octreotide—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000433	0.0005	CcSEcCtD
Octreotide—Fatigue—Mycophenolic acid—systemic scleroderma	0.000432	0.000499	CcSEcCtD
Octreotide—SSTR3—GPCR ligand binding—CCL2—systemic scleroderma	0.000431	0.00625	CbGpPWpGaD
Octreotide—Nausea—Mometasone—systemic scleroderma	0.000431	0.000498	CcSEcCtD
Octreotide—Anorexia—Lisinopril—systemic scleroderma	0.00043	0.000497	CcSEcCtD
Octreotide—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00043	0.000496	CcSEcCtD
Octreotide—Weight increased—Prednisone—systemic scleroderma	0.000429	0.000496	CcSEcCtD
Octreotide—Constipation—Mycophenolic acid—systemic scleroderma	0.000429	0.000495	CcSEcCtD
Octreotide—Pain—Mycophenolic acid—systemic scleroderma	0.000429	0.000495	CcSEcCtD
Octreotide—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000428	0.000495	CcSEcCtD
Octreotide—SSTR4—Signaling by GPCR—EDN1—systemic scleroderma	0.000427	0.00619	CbGpPWpGaD
Octreotide—Weight decreased—Prednisone—systemic scleroderma	0.000427	0.000493	CcSEcCtD
Octreotide—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000426	0.000492	CcSEcCtD
Octreotide—Hyperglycaemia—Prednisone—systemic scleroderma	0.000425	0.000491	CcSEcCtD
Octreotide—Cough—Mycophenolate mofetil—systemic scleroderma	0.000423	0.000489	CcSEcCtD
Octreotide—Dizziness—Captopril—systemic scleroderma	0.000422	0.000487	CcSEcCtD
Octreotide—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.00042	0.000485	CcSEcCtD
Octreotide—Depression—Prednisone—systemic scleroderma	0.000419	0.000484	CcSEcCtD
Octreotide—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000419	0.000484	CcSEcCtD
Octreotide—Urticaria—Leflunomide—systemic scleroderma	0.000417	0.000482	CcSEcCtD
Octreotide—Abdominal pain—Leflunomide—systemic scleroderma	0.000415	0.00048	CcSEcCtD
Octreotide—Body temperature increased—Leflunomide—systemic scleroderma	0.000415	0.00048	CcSEcCtD
Octreotide—SSTR1—GPCR ligand binding—CCL2—systemic scleroderma	0.000413	0.00599	CbGpPWpGaD
Octreotide—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000413	0.000477	CcSEcCtD
Octreotide—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000413	0.000477	CcSEcCtD
Octreotide—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000413	0.000477	CcSEcCtD
Octreotide—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000413	0.000477	CcSEcCtD
Octreotide—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000412	0.000476	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—SMAD7—systemic scleroderma	0.000412	0.00597	CbGpPWpGaD
Octreotide—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000411	0.000475	CcSEcCtD
Octreotide—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000411	0.000475	CcSEcCtD
Octreotide—Hypersensitivity—Azathioprine—systemic scleroderma	0.00041	0.000474	CcSEcCtD
Octreotide—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00041	0.000474	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00041	0.000474	CcSEcCtD
Octreotide—Insomnia—Lisinopril—systemic scleroderma	0.000408	0.000472	CcSEcCtD
Octreotide—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000408	0.000471	CcSEcCtD
Octreotide—Paraesthesia—Lisinopril—systemic scleroderma	0.000405	0.000468	CcSEcCtD
Octreotide—Vomiting—Captopril—systemic scleroderma	0.000405	0.000468	CcSEcCtD
Octreotide—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000404	0.000466	CcSEcCtD
Octreotide—Dyspnoea—Lisinopril—systemic scleroderma	0.000403	0.000465	CcSEcCtD
Octreotide—Rash—Captopril—systemic scleroderma	0.000402	0.000464	CcSEcCtD
Octreotide—Dermatitis—Captopril—systemic scleroderma	0.000402	0.000464	CcSEcCtD
Octreotide—Somnolence—Lisinopril—systemic scleroderma	0.000401	0.000464	CcSEcCtD
Octreotide—Headache—Captopril—systemic scleroderma	0.000399	0.000461	CcSEcCtD
Octreotide—Dyspepsia—Lisinopril—systemic scleroderma	0.000398	0.000459	CcSEcCtD
Octreotide—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000396	0.000458	CcSEcCtD
Octreotide—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000396	0.000458	CcSEcCtD
Octreotide—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000396	0.000457	CcSEcCtD
Octreotide—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000396	0.000457	CcSEcCtD
Octreotide—Asthma—Methotrexate—systemic scleroderma	0.000394	0.000455	CcSEcCtD
Octreotide—Infection—Mycophenolate mofetil—systemic scleroderma	0.000393	0.000454	CcSEcCtD
Octreotide—Decreased appetite—Lisinopril—systemic scleroderma	0.000393	0.000453	CcSEcCtD
Octreotide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00039	0.00045	CcSEcCtD
Octreotide—Fatigue—Lisinopril—systemic scleroderma	0.000389	0.00045	CcSEcCtD
Octreotide—Shock—Mycophenolate mofetil—systemic scleroderma	0.000389	0.00045	CcSEcCtD
Octreotide—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000388	0.000448	CcSEcCtD
Octreotide—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000387	0.000448	CcSEcCtD
Octreotide—Hypersensitivity—Leflunomide—systemic scleroderma	0.000387	0.000447	CcSEcCtD
Octreotide—Pancreatitis—Methotrexate—systemic scleroderma	0.000386	0.000446	CcSEcCtD
Octreotide—Constipation—Lisinopril—systemic scleroderma	0.000386	0.000446	CcSEcCtD
Octreotide—Pain—Lisinopril—systemic scleroderma	0.000386	0.000446	CcSEcCtD
Octreotide—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000386	0.000446	CcSEcCtD
Octreotide—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000384	0.000444	CcSEcCtD
Octreotide—Bradycardia—Prednisone—systemic scleroderma	0.000384	0.000444	CcSEcCtD
Octreotide—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000382	0.000442	CcSEcCtD
Octreotide—Diarrhoea—Azathioprine—systemic scleroderma	0.000381	0.00044	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—SMAD7—systemic scleroderma	0.00038	0.00551	CbGpPWpGaD
Octreotide—Nausea—Captopril—systemic scleroderma	0.000379	0.000438	CcSEcCtD
Octreotide—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000378	0.000437	CcSEcCtD
Octreotide—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000377	0.000436	CcSEcCtD
Octreotide—Asthenia—Leflunomide—systemic scleroderma	0.000377	0.000436	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—RHOB—systemic scleroderma	0.000375	0.00543	CbGpPWpGaD
Octreotide—Feeling abnormal—Lisinopril—systemic scleroderma	0.000372	0.00043	CcSEcCtD
Octreotide—Pruritus—Leflunomide—systemic scleroderma	0.000372	0.00043	CcSEcCtD
Octreotide—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000369	0.000427	CcSEcCtD
Octreotide—Dysuria—Methotrexate—systemic scleroderma	0.000369	0.000426	CcSEcCtD
Octreotide—Dizziness—Azathioprine—systemic scleroderma	0.000368	0.000425	CcSEcCtD
Octreotide—SSTR5—GPCR ligand binding—CCL2—systemic scleroderma	0.000367	0.00532	CbGpPWpGaD
Octreotide—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000366	0.000423	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.00036	0.000416	CcSEcCtD
Octreotide—Asthenia—Mycophenolic acid—systemic scleroderma	0.00036	0.000416	CcSEcCtD
Octreotide—Diarrhoea—Leflunomide—systemic scleroderma	0.00036	0.000415	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—RHOB—systemic scleroderma	0.000359	0.00521	CbGpPWpGaD
Octreotide—Urticaria—Lisinopril—systemic scleroderma	0.000359	0.000414	CcSEcCtD
Octreotide—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000358	0.000413	CcSEcCtD
Octreotide—Abdominal pain—Lisinopril—systemic scleroderma	0.000357	0.000412	CcSEcCtD
Octreotide—Body temperature increased—Lisinopril—systemic scleroderma	0.000357	0.000412	CcSEcCtD
Octreotide—SSTR3—GPCR downstream signaling—EDN1—systemic scleroderma	0.000357	0.00517	CbGpPWpGaD
Octreotide—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000355	0.00041	CcSEcCtD
Octreotide—Pruritus—Mycophenolic acid—systemic scleroderma	0.000355	0.00041	CcSEcCtD
Octreotide—Vomiting—Azathioprine—systemic scleroderma	0.000354	0.000409	CcSEcCtD
Octreotide—Pneumonia—Methotrexate—systemic scleroderma	0.000353	0.000408	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—HSPG2—systemic scleroderma	0.000353	0.00512	CbGpPWpGaD
Octreotide—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000353	0.000407	CcSEcCtD
Octreotide—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000352	0.000406	CcSEcCtD
Octreotide—Drowsiness—Methotrexate—systemic scleroderma	0.000351	0.000406	CcSEcCtD
Octreotide—Rash—Azathioprine—systemic scleroderma	0.000351	0.000405	CcSEcCtD
Octreotide—Dermatitis—Azathioprine—systemic scleroderma	0.000351	0.000405	CcSEcCtD
Octreotide—Depression—Methotrexate—systemic scleroderma	0.00035	0.000405	CcSEcCtD
Octreotide—Flushing—Prednisone—systemic scleroderma	0.00035	0.000405	CcSEcCtD
Octreotide—Headache—Azathioprine—systemic scleroderma	0.000349	0.000403	CcSEcCtD
Octreotide—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000348	0.000402	CcSEcCtD
Octreotide—Dizziness—Leflunomide—systemic scleroderma	0.000348	0.000401	CcSEcCtD
Octreotide—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000344	0.000397	CcSEcCtD
Octreotide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000343	0.000396	CcSEcCtD
Octreotide—SSTR1—GPCR downstream signaling—EDN1—systemic scleroderma	0.000342	0.00496	CbGpPWpGaD
Octreotide—Conjunctivitis—Methotrexate—systemic scleroderma	0.000342	0.000395	CcSEcCtD
Octreotide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000342	0.000395	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—CSK—systemic scleroderma	0.000341	0.00495	CbGpPWpGaD
Octreotide—Immune system disorder—Prednisone—systemic scleroderma	0.000341	0.000394	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—HSPG2—systemic scleroderma	0.000339	0.00491	CbGpPWpGaD
Octreotide—SSTR2—GPCR ligand binding—CCL2—systemic scleroderma	0.000338	0.00491	CbGpPWpGaD
Octreotide—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000338	0.000391	CcSEcCtD
Octreotide—Pain—Mycophenolate mofetil—systemic scleroderma	0.000338	0.000391	CcSEcCtD
Octreotide—Arrhythmia—Prednisone—systemic scleroderma	0.000337	0.00039	CcSEcCtD
Octreotide—Haematuria—Methotrexate—systemic scleroderma	0.000335	0.000387	CcSEcCtD
Octreotide—Vomiting—Leflunomide—systemic scleroderma	0.000334	0.000386	CcSEcCtD
Octreotide—Alopecia—Prednisone—systemic scleroderma	0.000334	0.000385	CcSEcCtD
Octreotide—Hypersensitivity—Lisinopril—systemic scleroderma	0.000333	0.000384	CcSEcCtD
Octreotide—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000332	0.000384	CcSEcCtD
Octreotide—Dizziness—Mycophenolic acid—systemic scleroderma	0.000332	0.000383	CcSEcCtD
Octreotide—Epistaxis—Methotrexate—systemic scleroderma	0.000331	0.000383	CcSEcCtD
Octreotide—Rash—Leflunomide—systemic scleroderma	0.000331	0.000383	CcSEcCtD
Octreotide—Dermatitis—Leflunomide—systemic scleroderma	0.000331	0.000382	CcSEcCtD
Octreotide—Mental disorder—Prednisone—systemic scleroderma	0.000331	0.000382	CcSEcCtD
Octreotide—Nausea—Azathioprine—systemic scleroderma	0.000331	0.000382	CcSEcCtD
Octreotide—Headache—Leflunomide—systemic scleroderma	0.000329	0.00038	CcSEcCtD
Octreotide—Erythema—Prednisone—systemic scleroderma	0.000329	0.00038	CcSEcCtD
Octreotide—Malnutrition—Prednisone—systemic scleroderma	0.000329	0.00038	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—CSK—systemic scleroderma	0.000327	0.00474	CbGpPWpGaD
Octreotide—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000326	0.000377	CcSEcCtD
Octreotide—Asthenia—Lisinopril—systemic scleroderma	0.000324	0.000374	CcSEcCtD
Octreotide—SSTR3—Signaling by GPCR—EDN1—systemic scleroderma	0.000324	0.00469	CbGpPWpGaD
Octreotide—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000324	0.000374	CcSEcCtD
Octreotide—Pruritus—Lisinopril—systemic scleroderma	0.000319	0.000369	CcSEcCtD
Octreotide—Vomiting—Mycophenolic acid—systemic scleroderma	0.000319	0.000368	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—RHOB—systemic scleroderma	0.000318	0.00462	CbGpPWpGaD
Octreotide—Rash—Mycophenolic acid—systemic scleroderma	0.000316	0.000365	CcSEcCtD
Octreotide—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000316	0.000365	CcSEcCtD
Octreotide—Hepatitis—Methotrexate—systemic scleroderma	0.000315	0.000364	CcSEcCtD
Octreotide—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000314	0.000363	CcSEcCtD
Octreotide—Headache—Mycophenolic acid—systemic scleroderma	0.000314	0.000363	CcSEcCtD
Octreotide—Pharyngitis—Methotrexate—systemic scleroderma	0.000313	0.000362	CcSEcCtD
Octreotide—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000313	0.000361	CcSEcCtD
Octreotide—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000313	0.000361	CcSEcCtD
Octreotide—Nausea—Leflunomide—systemic scleroderma	0.000312	0.000361	CcSEcCtD
Octreotide—SSTR1—Signaling by GPCR—EDN1—systemic scleroderma	0.00031	0.0045	CbGpPWpGaD
Octreotide—Vision blurred—Prednisone—systemic scleroderma	0.00031	0.000358	CcSEcCtD
Octreotide—Diarrhoea—Lisinopril—systemic scleroderma	0.000309	0.000357	CcSEcCtD
Octreotide—Ill-defined disorder—Prednisone—systemic scleroderma	0.000305	0.000352	CcSEcCtD
Octreotide—Visual impairment—Methotrexate—systemic scleroderma	0.000304	0.000351	CcSEcCtD
Octreotide—Anaemia—Prednisone—systemic scleroderma	0.000304	0.000351	CcSEcCtD
Octreotide—SSTR5—GPCR downstream signaling—EDN1—systemic scleroderma	0.000303	0.00439	CbGpPWpGaD
Octreotide—Agitation—Prednisone—systemic scleroderma	0.000302	0.000349	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—HSPG2—systemic scleroderma	0.0003	0.00435	CbGpPWpGaD
Octreotide—Dizziness—Lisinopril—systemic scleroderma	0.000299	0.000345	CcSEcCtD
Octreotide—Nausea—Mycophenolic acid—systemic scleroderma	0.000298	0.000344	CcSEcCtD
Octreotide—Malaise—Prednisone—systemic scleroderma	0.000296	0.000342	CcSEcCtD
Octreotide—Vertigo—Prednisone—systemic scleroderma	0.000295	0.000341	CcSEcCtD
Octreotide—Syncope—Prednisone—systemic scleroderma	0.000295	0.00034	CcSEcCtD
Octreotide—Tinnitus—Methotrexate—systemic scleroderma	0.000294	0.00034	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—RHOB—systemic scleroderma	0.000294	0.00426	CbGpPWpGaD
Octreotide—Cardiac disorder—Methotrexate—systemic scleroderma	0.000293	0.000338	CcSEcCtD
Octreotide—SSTR4—Signaling by GPCR—CCL2—systemic scleroderma	0.000292	0.00423	CbGpPWpGaD
Octreotide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000292	0.000337	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—CSK—systemic scleroderma	0.00029	0.00421	CbGpPWpGaD
Octreotide—Loss of consciousness—Prednisone—systemic scleroderma	0.000289	0.000334	CcSEcCtD
Octreotide—Vomiting—Lisinopril—systemic scleroderma	0.000287	0.000332	CcSEcCtD
Octreotide—Immune system disorder—Methotrexate—systemic scleroderma	0.000285	0.000329	CcSEcCtD
Octreotide—Rash—Lisinopril—systemic scleroderma	0.000285	0.000329	CcSEcCtD
Octreotide—Convulsion—Prednisone—systemic scleroderma	0.000285	0.000329	CcSEcCtD
Octreotide—Dermatitis—Lisinopril—systemic scleroderma	0.000284	0.000329	CcSEcCtD
Octreotide—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000284	0.000328	CcSEcCtD
Octreotide—Hypertension—Prednisone—systemic scleroderma	0.000284	0.000328	CcSEcCtD
Octreotide—Headache—Lisinopril—systemic scleroderma	0.000283	0.000327	CcSEcCtD
Octreotide—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.00028	0.000323	CcSEcCtD
Octreotide—Arthralgia—Prednisone—systemic scleroderma	0.00028	0.000323	CcSEcCtD
Octreotide—Myalgia—Prednisone—systemic scleroderma	0.00028	0.000323	CcSEcCtD
Octreotide—SSTR2—GPCR downstream signaling—EDN1—systemic scleroderma	0.00028	0.00406	CbGpPWpGaD
Octreotide—Anxiety—Prednisone—systemic scleroderma	0.000279	0.000322	CcSEcCtD
Octreotide—Alopecia—Methotrexate—systemic scleroderma	0.000279	0.000322	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000278	0.000321	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—HSPG2—systemic scleroderma	0.000277	0.00402	CbGpPWpGaD
Octreotide—Discomfort—Prednisone—systemic scleroderma	0.000276	0.000319	CcSEcCtD
Octreotide—Mental disorder—Methotrexate—systemic scleroderma	0.000276	0.000319	CcSEcCtD
Octreotide—SSTR5—Signaling by GPCR—EDN1—systemic scleroderma	0.000275	0.00399	CbGpPWpGaD
Octreotide—Erythema—Methotrexate—systemic scleroderma	0.000275	0.000317	CcSEcCtD
Octreotide—Malnutrition—Methotrexate—systemic scleroderma	0.000275	0.000317	CcSEcCtD
Octreotide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000271	0.000313	CcSEcCtD
Octreotide—Nausea—Lisinopril—systemic scleroderma	0.000268	0.00031	CcSEcCtD
Octreotide—Anaphylactic shock—Prednisone—systemic scleroderma	0.000268	0.00031	CcSEcCtD
Octreotide—Oedema—Prednisone—systemic scleroderma	0.000268	0.00031	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—CSK—systemic scleroderma	0.000268	0.00388	CbGpPWpGaD
Octreotide—Infection—Prednisone—systemic scleroderma	0.000266	0.000308	CcSEcCtD
Octreotide—Back pain—Methotrexate—systemic scleroderma	0.000266	0.000307	CcSEcCtD
Octreotide—Shock—Prednisone—systemic scleroderma	0.000264	0.000305	CcSEcCtD
Octreotide—Nervous system disorder—Prednisone—systemic scleroderma	0.000263	0.000304	CcSEcCtD
Octreotide—Tachycardia—Prednisone—systemic scleroderma	0.000262	0.000302	CcSEcCtD
Octreotide—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000262	0.000302	CcSEcCtD
Octreotide—Skin disorder—Prednisone—systemic scleroderma	0.000261	0.000301	CcSEcCtD
Octreotide—Hyperhidrosis—Prednisone—systemic scleroderma	0.000259	0.0003	CcSEcCtD
Octreotide—Vision blurred—Methotrexate—systemic scleroderma	0.000259	0.000299	CcSEcCtD
Octreotide—Anorexia—Prednisone—systemic scleroderma	0.000256	0.000295	CcSEcCtD
Octreotide—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000255	0.000294	CcSEcCtD
Octreotide—SSTR2—Signaling by GPCR—EDN1—systemic scleroderma	0.000254	0.00368	CbGpPWpGaD
Octreotide—Anaemia—Methotrexate—systemic scleroderma	0.000254	0.000293	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—EDN1—systemic scleroderma	0.000252	0.00366	CbGpPWpGaD
Octreotide—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000252	0.000291	CcSEcCtD
Octreotide—Rash—Mycophenolate mofetil—systemic scleroderma	0.000249	0.000288	CcSEcCtD
Octreotide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000249	0.000288	CcSEcCtD
Octreotide—Headache—Mycophenolate mofetil—systemic scleroderma	0.000248	0.000286	CcSEcCtD
Octreotide—Malaise—Methotrexate—systemic scleroderma	0.000248	0.000286	CcSEcCtD
Octreotide—Vertigo—Methotrexate—systemic scleroderma	0.000247	0.000285	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000244	0.000282	CcSEcCtD
Octreotide—Insomnia—Prednisone—systemic scleroderma	0.000243	0.00028	CcSEcCtD
Octreotide—Paraesthesia—Prednisone—systemic scleroderma	0.000241	0.000278	CcSEcCtD
Octreotide—Cough—Methotrexate—systemic scleroderma	0.00024	0.000277	CcSEcCtD
Octreotide—Convulsion—Methotrexate—systemic scleroderma	0.000238	0.000275	CcSEcCtD
Octreotide—Dyspepsia—Prednisone—systemic scleroderma	0.000236	0.000273	CcSEcCtD
Octreotide—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000235	0.000271	CcSEcCtD
Octreotide—Myalgia—Methotrexate—systemic scleroderma	0.000234	0.00027	CcSEcCtD
Octreotide—Arthralgia—Methotrexate—systemic scleroderma	0.000234	0.00027	CcSEcCtD
Octreotide—Chest pain—Methotrexate—systemic scleroderma	0.000234	0.00027	CcSEcCtD
Octreotide—Decreased appetite—Prednisone—systemic scleroderma	0.000233	0.000269	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000232	0.000268	CcSEcCtD
Octreotide—Fatigue—Prednisone—systemic scleroderma	0.000231	0.000267	CcSEcCtD
Octreotide—Discomfort—Methotrexate—systemic scleroderma	0.000231	0.000267	CcSEcCtD
Octreotide—Constipation—Prednisone—systemic scleroderma	0.000229	0.000265	CcSEcCtD
Octreotide—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000224	0.000259	CcSEcCtD
Octreotide—Infection—Methotrexate—systemic scleroderma	0.000223	0.000257	CcSEcCtD
Octreotide—SSTR3—Signaling by GPCR—CCL2—systemic scleroderma	0.000221	0.00321	CbGpPWpGaD
Octreotide—Feeling abnormal—Prednisone—systemic scleroderma	0.000221	0.000255	CcSEcCtD
Octreotide—Nervous system disorder—Methotrexate—systemic scleroderma	0.00022	0.000254	CcSEcCtD
Octreotide—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000219	0.000254	CcSEcCtD
Octreotide—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000219	0.000253	CcSEcCtD
Octreotide—Skin disorder—Methotrexate—systemic scleroderma	0.000218	0.000252	CcSEcCtD
Octreotide—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000217	0.00025	CcSEcCtD
Octreotide—Anorexia—Methotrexate—systemic scleroderma	0.000214	0.000247	CcSEcCtD
Octreotide—Urticaria—Prednisone—systemic scleroderma	0.000213	0.000246	CcSEcCtD
Octreotide—SSTR1—Signaling by GPCR—CCL2—systemic scleroderma	0.000212	0.00308	CbGpPWpGaD
Octreotide—Body temperature increased—Prednisone—systemic scleroderma	0.000212	0.000245	CcSEcCtD
Octreotide—Abdominal pain—Prednisone—systemic scleroderma	0.000212	0.000245	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000204	0.000236	CcSEcCtD
Octreotide—Insomnia—Methotrexate—systemic scleroderma	0.000203	0.000234	CcSEcCtD
Octreotide—Paraesthesia—Methotrexate—systemic scleroderma	0.000201	0.000233	CcSEcCtD
Octreotide—Dyspnoea—Methotrexate—systemic scleroderma	0.0002	0.000231	CcSEcCtD
Octreotide—Somnolence—Methotrexate—systemic scleroderma	0.000199	0.00023	CcSEcCtD
Octreotide—Hypersensitivity—Prednisone—systemic scleroderma	0.000198	0.000228	CcSEcCtD
Octreotide—Dyspepsia—Methotrexate—systemic scleroderma	0.000197	0.000228	CcSEcCtD
Octreotide—Decreased appetite—Methotrexate—systemic scleroderma	0.000195	0.000225	CcSEcCtD
Octreotide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000194	0.000224	CcSEcCtD
Octreotide—Fatigue—Methotrexate—systemic scleroderma	0.000193	0.000223	CcSEcCtD
Octreotide—Asthenia—Prednisone—systemic scleroderma	0.000192	0.000222	CcSEcCtD
Octreotide—Pain—Methotrexate—systemic scleroderma	0.000192	0.000221	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—EDN1—systemic scleroderma	0.000191	0.00277	CbGpPWpGaD
Octreotide—Pruritus—Prednisone—systemic scleroderma	0.00019	0.000219	CcSEcCtD
Octreotide—SSTR5—Signaling by GPCR—CCL2—systemic scleroderma	0.000188	0.00273	CbGpPWpGaD
Octreotide—Feeling abnormal—Methotrexate—systemic scleroderma	0.000185	0.000213	CcSEcCtD
Octreotide—Diarrhoea—Prednisone—systemic scleroderma	0.000184	0.000212	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—EDN1—systemic scleroderma	0.000183	0.00266	CbGpPWpGaD
Octreotide—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000183	0.000212	CcSEcCtD
Octreotide—Urticaria—Methotrexate—systemic scleroderma	0.000178	0.000206	CcSEcCtD
Octreotide—Dizziness—Prednisone—systemic scleroderma	0.000177	0.000205	CcSEcCtD
Octreotide—Body temperature increased—Methotrexate—systemic scleroderma	0.000177	0.000205	CcSEcCtD
Octreotide—Abdominal pain—Methotrexate—systemic scleroderma	0.000177	0.000205	CcSEcCtD
Octreotide—SSTR2—Signaling by GPCR—CCL2—systemic scleroderma	0.000174	0.00252	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CCL2—systemic scleroderma	0.000173	0.0025	CbGpPWpGaD
Octreotide—Vomiting—Prednisone—systemic scleroderma	0.000171	0.000197	CcSEcCtD
Octreotide—Rash—Prednisone—systemic scleroderma	0.000169	0.000195	CcSEcCtD
Octreotide—Dermatitis—Prednisone—systemic scleroderma	0.000169	0.000195	CcSEcCtD
Octreotide—Headache—Prednisone—systemic scleroderma	0.000168	0.000194	CcSEcCtD
Octreotide—Hypersensitivity—Methotrexate—systemic scleroderma	0.000165	0.000191	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—EDN1—systemic scleroderma	0.000163	0.00236	CbGpPWpGaD
Octreotide—Asthenia—Methotrexate—systemic scleroderma	0.000161	0.000186	CcSEcCtD
Octreotide—Nausea—Prednisone—systemic scleroderma	0.000159	0.000184	CcSEcCtD
Octreotide—Pruritus—Methotrexate—systemic scleroderma	0.000159	0.000183	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—NOS3—systemic scleroderma	0.000154	0.00223	CbGpPWpGaD
Octreotide—Diarrhoea—Methotrexate—systemic scleroderma	0.000153	0.000177	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—EDN1—systemic scleroderma	0.00015	0.00218	CbGpPWpGaD
Octreotide—Dizziness—Methotrexate—systemic scleroderma	0.000148	0.000171	CcSEcCtD
Octreotide—Vomiting—Methotrexate—systemic scleroderma	0.000143	0.000165	CcSEcCtD
Octreotide—Rash—Methotrexate—systemic scleroderma	0.000141	0.000163	CcSEcCtD
Octreotide—Dermatitis—Methotrexate—systemic scleroderma	0.000141	0.000163	CcSEcCtD
Octreotide—Headache—Methotrexate—systemic scleroderma	0.00014	0.000162	CcSEcCtD
Octreotide—Nausea—Methotrexate—systemic scleroderma	0.000133	0.000154	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—CCL2—systemic scleroderma	0.000131	0.0019	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CCL2—systemic scleroderma	0.000125	0.00182	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—MMP9—systemic scleroderma	0.000123	0.00179	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—NOS3—systemic scleroderma	0.000117	0.00169	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—NOS3—systemic scleroderma	0.000112	0.00162	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CCL2—systemic scleroderma	0.000111	0.00161	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CCL2—systemic scleroderma	0.000103	0.00149	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—TGFB1—systemic scleroderma	0.000102	0.00147	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—NOS3—systemic scleroderma	9.91e-05	0.00144	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—MMP9—systemic scleroderma	9.35e-05	0.00136	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—NOS3—systemic scleroderma	9.14e-05	0.00133	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—MMP9—systemic scleroderma	8.96e-05	0.0013	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—MMP9—systemic scleroderma	7.95e-05	0.00115	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—TGFB1—systemic scleroderma	7.71e-05	0.00112	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—TGFB1—systemic scleroderma	7.39e-05	0.00107	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—MMP9—systemic scleroderma	7.34e-05	0.00106	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—TGFB1—systemic scleroderma	6.55e-05	0.00095	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—TGFB1—systemic scleroderma	6.05e-05	0.000877	CbGpPWpGaD
